Sarah D. Busslinger

Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.

R. Schibli, C. Müller, M. Benešová, 2022, Molecular pharmaceutics.

[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617

R. Schibli, C. Müller, Z. Talip, 2022, Cancers.

Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

F. Borgna, R. Schibli, P. Bernhardt, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy

R. Schibli, P. Grundler, P. Bernhardt, 2023, The Journal of Nuclear Medicine.

Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.

F. Borgna, R. Schibli, C. Müller, 2022, Molecular pharmaceutics.